申请人:Sandoz Pharmaceuticals Corp.
公开号:US04910206A1
公开(公告)日:1990-03-20
The invention discloses certain 5-hetero or aryl-substituted-imidazo[2,1-a]isoquinolines useful as platelet activating factor (PAF) receptor antagonists, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-mediated bronchoconstriction and extravassation and PAF-mediated, endotoxin-induced lung injury, and for controlling hyperreactive airways induced by PAF or allergin. In addition, the invention discloses the use of a select group of said compounds as anti-tumor agents.
本发明公开了某些5-杂环或芳基取代的咪唑并[2,1-a]异喹啉,其作为血小板活化因子(PAF)受体拮抗剂,含有该化合物作为活性成分的制药组合物以及使用这种组合物的方法,用于抑制PAF介导的支气管收缩和渗出以及PAF介导的内毒素诱导的肺损伤,并控制由PAF或过敏原引起的高反应性气道。此外,本发明公开了一组选择性的化合物用作抗肿瘤剂。